Table 3.
Percentage of patients who showed a decrease (minimally important difference) in quality-of-life scores from own baseline scores
| Domains | Follow-up (months) | ||||
|---|---|---|---|---|---|
| % (n) | |||||
| 1 | 3 | 6 | 12 | 24 | |
| Urinary summary | |||||
| IMRT | 36 (44/123) | 25 (31/123) | 24 (29/121) | 26 (31/121) | 28 (34/121) |
| BT | 73 (165/227) | 69 (156/227) | 60 (136/227) | 35 (79/227) | 43 (95/221) |
| BT + 3D-CRT | 64 (131/205) | 84 (173/205) | 58 (118/205) | 40 (83/205) | 54 (114/201) |
| Bowel summary | |||||
| IMRT | 52 (64/123) | 41 (50/123) | 33 (40/121) | 45 (54/121) | 43 (52/121) |
| BT | 40 (91/227) | 37 (84/227) | 37 (85/227) | 31 (70/227) | 29 (64/221) |
| BT + 3D-CRT | 39 (80/205) | 68 (139/205) | 46 (95/205) | 41 (84/205) | 46 (92/201) |
| Sexual summary | |||||
| IMRT | 31 (22/123) | 23 (28/123) | 25 (30/121) | 21 (25/121) | 28 (34/121) |
| BT | 27 (62/227) | 23 (52/227) | 26 (58/227) | 26 (58/227) | 28 (62/221) |
| BT + 3D-CRT | 15 (30/205) | 17(34/205) | 15 (30/205) | 18 (36/205) | 16 (33/201) |
| Hormone summary | |||||
| IMRT | 40 (49/123) | 34 (42/123) | 32 (39/121) | 36 (44/121) | 32 (39/121) |
| BT | 21(40/227) | 22 (49/227) | 18 (40/227) | 15 (35/227) | 14 (31/221) |
| BT + 3D-CRT | 25 (51/205) | 24 (49/205) | 19 (39/205) | 22 (46/205) | 23 (47/201) |
EPIC = Expanded Prostate Cancer Index Composite, IMRT = intensity-modulated radiation therapy, IPSS = International Prostate Symptom Score, QOL = quality of life, BT = brachytherapy, 3D-CRT = 3D conformal radiation therapy, SD = standard deviation.